[1] Saab S, Kullar R, Gounder P. The urgent need for hepatitis C screening in pregnant women: a call to action. Obstet Gynecol, 2020; 135, 773−7. doi:  10.1097/AOG.0000000000003704
[2] Cafardi JM, Lin HT, Lange L, et al. Vertical transmission of hepatitis C virus among women with a history of injection opioid use. Clin Infect Dis, 2024; 79, 701−4. doi:  10.1093/cid/ciae177
[3] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization. 2016.
[4] Yew KC, Tan QR, Lim PC, et al. Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol, 2024; 397, 1421−31. doi:  10.1007/s00210-023-02716-x
[5] Vaziri A, Gimson A, Agarwal K, et al. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. J Viral Hepat, 2019; 26, 231−5. doi:  10.1111/jvh.13022
[6] Rana R, Dangal R, Singh Y, et al. Hepatitis C virus infection in pregnancy and children: its implications and treatment considerations with directly acting antivirals: a review. JNMA J Nepal Med Assoc, 2021; 59, 942−53. doi:  10.31729/jnma.5501
[7] Jhaveri R, Yee LM, Antala S, et al. Responsible inclusion of pregnant individuals in eradicating HCV. Hepatology, 2021; 74, 1645−51. doi:  10.1002/hep.31825
[8] Hood RB, Norris AH, Shoben A, et al. Forecasting hepatitis C virus status for children in the United States: a modeling study. Clin Infect Dis, 2024; 79, 443−50. doi:  10.1093/cid/ciae157
[9] Jin HZ, Huang DM, Guan XJ. Practical neonatology. 3rd ed. People's Medical Publishing House. 2003. (In Chinese)
[10] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016; 63, 261−83. doi:  10.1002/hep.28156
[11] Ito M, Liu J, Fukasawa M, et al. Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation. JHEP Rep, 2025; 7, 101225. doi:  10.1016/j.jhepr.2024.101225
[12] Wu P, Wang Y, Ye Y, et al. Liver biomarkers, lipid metabolites, and risk of gestational diabetes mellitus in a prospective study among Chinese pregnant women. BMC Med, 2023; 21, 150. doi:  10.1186/s12916-023-02818-6
[13] Liu H, Zhang LB, Cheng HY, et al. The associations of maternal liver biomarkers in early pregnancy with the risk of gestational diabetes mellitus: a prospective cohort study and Mendelian randomization analysis. Front Endocrinol, 2024; 15, 1396347. doi:  10.3389/fendo.2024.1396347
[14] Khadir F, Rahimi Z, Vaisi-Raygani A, et al. Gestational diabetes mellitus (GDM), hypothyroidism, and gene variants (Keap1 Rs11085735) in patients with preeclampsia. Rep Biochem Mol Biol, 2022; 11, 493−501.
[15] Wang SX, Cui ZF, Yang HX. Interactions between host and gut microbiota in gestational diabetes mellitus and their impacts on offspring. BMC Microbiol, 2024; 24, 161. doi:  10.1186/s12866-024-03255-y
[16] Velloso LA, Folli F, Saad MJ. TLR4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. Endocr Rev, 2015; 36, 245−71. doi:  10.1210/er.2014-1100
[17] Tacke F, Boeker KHW, Klinker H, et al. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int, 2020; 40, 539−48. doi:  10.1111/liv.14186
[18] Tacke F, Klinker H, Boeker KHW, et al. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: data from the German hepatitis C-registry. Hepatol Commun, 2022; 6, 2488−95. doi:  10.1002/hep4.2015
[19] Krupa P, Wein H, Zemmrich LS, et al. Pregnancy-related factors induce immune tolerance through regulation of sCD83 release. Front Immunol, 2024; 15, 1452879. doi:  10.3389/fimmu.2024.1452879
[20] Bellarosa C, Bedogni G, Bianco A, et al. Association of serum bilirubin level with metabolic syndrome and non-alcoholic fatty liver disease: a cross-sectional study of 1672 obese children. J Clin Med, 2021; 10, 2812. doi:  10.3390/jcm10132812
[21] Wake T, Tateishi R, Fukumoto T, et al. Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. PLoS One, 2020; 15, e0231836. doi:  10.1371/journal.pone.0231836
[22] Nakajima T, Karino Y, Hige S, et al. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. J Gastroenterol Hepatol, 2021; 36, 367−75. doi:  10.1111/jgh.15280
[23] Zuñiga-Aguilar E, Ramírez-Fernández O. Fibrosis and hepatic regeneration mechanism. Transl Gastroenterol Hepatol, 2022; 7, 9. doi:  10.21037/tgh.2020.02.21
[24] Pan CQ, Zhu BS, Xu JP, et al. Pregnancy and fetal outcomes of chronic hepatitis C mothers with viremia in China. World J Gastroenterol, 2022; 28, 5023−35. doi:  10.3748/wjg.v28.i34.5023
[25] Brits H, Adendorff J, Huisamen D, et al. The prevalence of neonatal jaundice and risk factors in healthy term neonates at National District Hospital in Bloemfontein. Afr J Prim Health Care Fam Med, 2018; 10, a1582.
[26] Belay HG, Debebe GA, Ayele AD, et al. Determinants of neonatal jaundice in Ethiopia: a systematic review and meta-analysis. World J Pediatr, 2022; 18, 725−33. doi:  10.1007/s12519-022-00597-3
[27] Bante A, Ahmed M, Degefa N, et al. Neonatal jaundice and associated factors in public hospitals of southern Ethiopia: a multi-center cross-sectional study. Heliyon, 2024; 10, e24838. doi:  10.1016/j.heliyon.2024.e24838
[28] Ding JH, Maxwell A, Adzibolosu N, et al. Mechanisms of immune regulation by the placenta: role of type I interferon and interferon-stimulated genes signaling during pregnancy. Immunol Rev, 2022; 308, 9−24. doi:  10.1111/imr.13077
[29] Nie QH, Gao LH, Cheng YQ, et al. Hepatitis C virus infection of human cytotrophoblasts cultured in vitro. J Med Virol, 2012; 84, 1586−92. doi:  10.1002/jmv.23380
[30] Napodano C, Ciasca G, Chiusolo P, et al. Serological and molecular characterization of hepatitis C virus-related cryoglobulinemic vasculitis in patients without cryoprecipitate. Int J Mol Sci, 2023; 24, 11602. doi:  10.3390/ijms241411602
[31] de Souza Lima B, Sanches APV, Ferreira MS, et al. Maternal-placental axis and its impact on fetal outcomes, metabolism, and development. Biochim Biophys Acta (BBA)-Mol Basis Dis, 2024; 1870, 166855. doi:  10.1016/j.bbadis.2023.166855
[32] Diniz MS, Hiden U, Falcão-Pires I, et al. Fetoplacental endothelial dysfunction in gestational diabetes mellitus and maternal obesity: a potential threat for programming cardiovascular disease. Biochim Biophys Acta (BBA)-Mol Basis Dis, 2023; 1869, 166834. doi:  10.1016/j.bbadis.2023.166834
[33] Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology, 2020; 71, 686−721. doi:  10.1002/hep.31060